Previously, our group and others have demonstrated a causative relationship between severe hypertriglyceridaemia and atherogenesis in mice. Furthermore, clinical investigations have shown high levels of plasma Apolipoprotein C-III (ApoCIII) associated with hypertriglyceridaemia and even cardiovascular disease. However, it remains unclear whether ApoCIII affects restenosis in vivo, and whether such an effect is mediated by ApoCIII alone, or in combination with hypertriglyceridaemia. We sought to investigate ApoCIII in restenosis and clarify how smooth muscle cells (SMCs) respond to authentic triglyceride-rich lipoproteins (TRLs) with or without ApoCIII (TRLs + ApoCIII).
Introduction
The role of hypertriglyceridaemia (HTG) in clinical cardiovascular disease (CVD), either as a direct cause or merely as a marker, remains a topic of debate. Our laboratory and others have established a causative relationship between HTG and atherosclerosis using the extreme HTG animal models lipoprotein lipase knockout (LPL2/2) and glycosylphosphatidylinositol-anchored high-density lipoproteinbinding protein 1-deficient (GPIHBP12/2) mice. 1, 2 Apolipoprotein C-III (ApoCIII) is a small, 79 amino acid glycoprotein, synthesized mainly in the liver and intestine. It plays a critical role in triglyceride metabolism, and the plasma concentration of ApoCIII has been shown to correlate positively with HTG in both human and mouse studies. 3 -12 Moreover, while Pollin et al. discovered the cardiacprotective association of an ApoCIII null mutation in Amish people, 13 recent larger studies have further demonstrated that loss-of-function mutations in ApoCIII are associated with lower levels of plasma triglyceride (TG), higher levels of high-density lipoprotein-cholesterol (HDL-C), and decreased incidence of coronary heart disease in the general population. 14 -16 Plasma ApoCIII serves as a major protein component of triglyceride-rich lipoproteins (TRLs), which include very low-density lipoproteins (VLDLs) and chylomicrons (CMs). Several studies have shown that TRLs can induce inflammatory responses in monocytes and endothelial cells (ECs). 17 -19 However, human studies have revealed that the VLDL, ApoCIII, is a more independently specific predictor of CVD risk than plasma TGs. 7, 20 Indeed, ApoCIII has been shown to induce EC activation and subsequent monocyte recruitment, activation, and adhesion to ECs. 21 -23 Notably, these findings were mainly obtained from in vitro studies on ECs and monocytes/macrophages, and clinical human investigations. Presently, there is a lack of direct evidence on whether and how ApoCIII-associated HTG affects neointimal formation and atherosclerotic lesion development in vivo.
Unlike the extensively studied role of ECs and monocytes/macrophages in hypertriglyceridaemia, there is little research showing whether and how smooth muscle cells (SMCs) respond to TRLs in this setting. It is already known that SMCs play an important role in atherosclerotic and neointimal development. 24 -27 Therefore, we first performed guide wire injury to carotid arteries of ApoCIII transgenic (ApoCIIItg) mice, a mouse model of ApoCIII overexpression, and ApoCIII-deficient (ApoCIII2/2) mice. Using this model of restenosis, SMCs were shown to play a more dominant role in neointimal formation 28 compared with atherosclerosis disease models in which ECs are intact. To distinguish the effect between HTG and ApoCIII, as it is impossible to distinguish them currently in vivo, we planned to use TRLs with or without ApoCIII (TRLs + ApoCIII), obtained from the plasma of ApoCIIItg and ApoCIII2/2 mice. However, it is difficult to isolate TRLs2ApoCIII from plasma of ApoCIII2/2 mice, due to low levels of TG and TRLs shown in previous in vitro studies 21, 23 which could only use either purified ApoCIII protein added directly to culture systems (in which case, hydrophobic ApoCIII may not function properly) or TRLs + ApoCIII obtained by immunoaffinity chromatography (in which case, too many purification steps may alter the physical structure and natural function of lipoproteins). To circumvent this problem, we used GPIHBP12/2 mice. These mice exhibit extreme HTG due to impaired anchoring of LPL to ECs, where LPLs exert catalytic activity. By crossing GPIHBP12/2 mice with ApoCIIItg or ApoCIII2/2 mice, authentic TRLs + ApoCIII can be easily harvested by a simple ultracentrifugation of the plasma from these mice.
We then focused on SMC proliferation in response to TRLs + ApoCIII. One possible mechanism involved in this proliferation response is oxidative stress. Reacive oxygen species (ROS) have been widely identified as a substantial promoting factor for vascular SMC proliferation. 29 -32 One pathway involved in SMC proliferation is the Akt pathway. 33 Therefore, using our animal models and SMC cultures, we examined ROS production to determine what role oxidative stress may play in the response to TRLs + ApoCIII.
Methods
An expanded Supplementary material online, Materials and Methods section is available online. For guide wire injury, 8-week old male ApoCIIItg, ApoCIII/Ldlr double knockout (DKO), and wild-type (WT) littermates, fed a chow diet, were used. WT littermates of ApoCIIItg and ApoCIII2/2 mice were generated separately and then pooled together as one WT control group for direct comparison. This was also done for Ldlr2/2 control mice used in the atherosclerosis study.
For atherosclerosis, 8-week old male ApoCIIItg/Ldlr2/2, ApoCIII/Ldlr DKO, and Ldlr2/2 littermate control mice were fed a high-fat, cholesterolrich pro-atherogenic diet (20% lard and 0.5% cholesterol) for 3 months before sacrifice and tissue harvest.
For cell culture studies, ECs and SMCs were incubated with authentic TRLs + ApoCIII isolated from ApoCIIItg/GPIHBP12/2 and ApoCIII/GPIHBP1 DKO mice. Cell proliferation, oxidative status, and related signalling pathways were then determined.
All data are presented as the mean + SEM. Statistical comparison was performed using Student's t-test or one-way analysis of variance (ANOVA) with a Bonferroni multiple comparison post-hoc test. A value of P , 0.05 was considered statistically significant.
Results

ApoCIIItg mice exhibit extreme hypertriglyceridaemia with or without the LDL receptor
It was first determined whether the ApoCIIItg mouse was an appropriate model of HTG. It was found that ApoCIIItg mice had almost 10-fold more plasma TG, whereas the plasma total cholesterol (TC) level was only mildly elevated, compared with WT and ApoCIII2/2 mice. In addition, there was a reduction of plasma HDL-C in ApoCIIItg mice ( Figure 1A) .
Furthermore, when compared with Ldlr2/2 and ApoCIII/Ldlr DKO mice, plasma TG levels in ApoCIIItg/Ldlr2/2 mice were also 10-fold higher and plasma TC was two-fold higher, irrespective of whether levels were tested before or after feeding mice the atherogenic diet ( Figure 1C) . The size distribution of lipoprotein particles in WT, ApoCIIItg, ApoCIII2/2, Ldlr2/2, ApoCIIItg/Ldlr2/2, and ApoCIII/Ldlr DKO mice was studied using fast protein liquid chromatography (FPLC). As expected, ApoCIIItg and ApoCIIItg/Ldlr2/2 mice exhibited a significant increase in TRLs in lipoprotein profiles compared with WT, ApoCIII2/2, Ldlr2/2, or ApoCIII/Ldlr DKO mice ( Figure 1B and D) .
These lipid profiles suggested that ApoCIIItg and ApoCIII/Ldlr DKO mice were suitable HTG models for restenosis and atherosclerosis research.
The ApoCIII transgene enhances atherosclerotic lesion development
In order to investigate the role of ApoCIII in atherogenesis, ApoCIIItg/ Ldlr2/2 and ApoCIII/Ldlr DKO mice, along with Ldlr2/2 littermates, were fed an atherogenic diet for 12 weeks. Atherosclerotic lesion size in the aorta root and en face area was then measured.
As shown in Figure 2A and B, ApoCIIItg/Ldlr2/2 mice experienced increased atherosclerotic lesions, both at the aorta root and at the en face area. However, a significant difference in lesion size between ApoCIII/ Ldlr DKO and Ldlr2/2 mice was not seen.
Different cell types in the lesion of the aortic sinus were identified by immunohistochemical staining for SM22a, an SMC marker, and Mac-3, a macrophage marker. The presence of the ApoCIII transgene led to increased SM22a and Mac-3 expression in lesion areas ( Figure 2C ). The expression of vascular cell adhesion protein-1 (VCAM-1), which is involved in monocyte and lymphocyte recruitment, was also significantly increased in lesion areas ( Figure 2C ). This suggested enhanced inflammation in the aortic sinus of ApoCIIItg/Ldlr2/2 mice.
We then investigated possible mechanisms involved in this process. A previous study demonstrated that renal patients were characterized by higher oxidative stress and inflammation, where inflammation correlated strongly with TG and ApoCIII but not with either TC or LDL-C. In addition, another study has shown that VLDL in metabolic syndrome may increase ROS production in ECs. 35 Therefore, to determine the effect of the ApoCIII transgene on vascular oxidative stress, we visualized superoxide production in fresh-frozen sections of mouse aorta using dihydroethidium (DHE) staining. As shown in Figure 2D , quantification of DHE fluorescence revealed a 1.8-fold increase in ApoCIIItg/ Ldlr2/2 aorta compared with the aorta of Ldlr2/2 mice.
ApoCIIItg mice have increased neointimal lesion formation after carotid artery endothelial denudation
Endothelial denudation of carotid arteries was performed on 8-week-old male ApoCIIItg, ApoCIII2/2, and WT mice. Injured arteries were processed for morphological analysis 14 days later. Medial thickness, intimal area, medial area, and the intimal/medial area ratio (I/M ratio) of all injured arteries were enumerated. As shown in Figure 3A , the ApoCIIItg mice had significantly increased neointimal formation compared with ApoCIII2/2 and WT mice. There was no statistical difference in neointima formation between ApoCIII2/2 mice and WT controls. This will be discussed further in detail later. Immunohistochemical staining of SM22a revealed that SMCs are a major cell constituting the neointima and media ( Figure 3B) . To evaluate the proportion of SMCs undergoing proliferation, we calculated the percentage of cell nuclei positive for the proliferating cell nuclear antigen (PCNA) in the neointima and media, where proliferating cells express PCNA, and that was measured using a proliferation index (PI). Immunofluorescent images showed that proliferating cells in injured Apolipoprotein CIII and atherogenosis arteries of ApoCIIItg mice were dramatically elevated in both the media and neointima ( Figure 4A and B) .
Immunohistochemistry data demonstrated that VCAM-1 and Mac-3 expression at neointimal sites of ApoCIIItg mice were significantly upregulated compared with ApoCIII2/2 and WT mice ( Figure 3B ). This result indicated that like ECs, SMCs may also express VCAM-1 and be involved in macrophage infiltration during neointimal formation and that the ApoCIII transgene could promote the process.
TRLs 1 ApoCIII enhance the inflammatory response in ECs
To confirm the purity of TRLs + ApoCIII in relation to ApoCIII content, normalized to reflect TG content, we analysed ApoCIII levels in TRLs + ApoCIII preparations by western blot. As expected, ApoCIII in TRLs2ApoCIII was absent, while a large amount of transgenic human ApoCIII in addition to endogenous murine ApoCIII was present in TRLs + ApoCIII ( Figure 5A) .
Endothelial-mediated monocyte recruitment is the initial step in the development of atherosclerotic lesions. 36 VCAM-1 is an inducible molecule expressed on ECs and known to mediate endothelial adhesion of monocytes and T lymphocytes. 37 Therefore, to determine whether VCAM-1 was up-regulated using our model, we incubated starved human umbilical vein endothelial cells (HUVECs) with TRLs + ApoCIII in vitro. After co-stimulation of HUVECs with 40 ng/mL tumour necrosis factor-a (TNF-a), TRLs + ApoCIII significantly up-regulated VCAM-1 expression compared with TRLs2ApoCIII ( Figure 5B) , while TRLs (100 mg/mL) alone could not stimulate VCAM-1 expression (data not shown). We next sought to examine different signalling pathways that may be involved in this process. The activation of the Akt and Erk1/2 mitogenactivated protein kinase (MAPK) signalling molecules in HUVECs was assessed after exposure to TRLs for 5 -30 min. TRLs + ApoCIII induced rapid phosphorylation of Akt and Erk1/2 ( Figure 5C ).
TRLs 1 ApoCIII significantly induce SMC proliferation
Since SMCs are major cells that constitute the neointima, and ApoCIII increased PCNA-positive cells in lesion sites, we next investigated the in vitro effect of TRLs + ApoCIII on SMC proliferation. Rat SMC number was quantified by CCK8 ( Figure 6A ) and bromodeoxyuridine (BrdU) incorporation ( Figure 6B ) at 24 and 48 h. It was found that TRLs + ApoCIII significantly promoted SMC proliferation compared with TRLs2ApoCIII. To assess whether mouse SMCs respond differently from rat SMCs to human and mouse ApoCIII, we isolated mouse SMCs to repeat BrdU incorporation ( Figure 6B, right) . The result was similar to that for rat SMCs. Since rat SMCs are much easier to obtain and culture, we then used rat SMCs to complete our subsequent experiments.
In SMCs treated with TRLs + ApoCIII for 48 h, PCNA levels detected by western blot were more than two-fold higher than those in TRLs2ApoCIII-treated SMCs. In addition, our results showed that TRLs + ApoCIII promoted PCNA expression in a concentrationdependent manner. In contrast, TRLs2ApoCIII failed to stimulate PCNA expression, where a high dose of TRLs2ApoCIII (≥200 mg/mL TG) did not change PCNA expression ( Figure 6C and D) .
Consistent with the in vivo study, VCAM-1 expression on SMCs exposed to TRLs + ApoCIII was up-regulated in a dose-dependent manner and VCAM-1 expression was 3.5-fold higher compared with Dulbecco's modified Eagle's medium (DMEM) blank controls after 48 h.
To determine the mechanism of the role of ApoCIIIs in SMC proliferation and VCAM-1 expression, we studied the effect of TRLs + ApoCIII on SMC signalling pathways. Alteration in the phosphorylation of Akt, one of the major pathways for SMC proliferation, was evaluated in response to TRLs. Serum-starved SMCs were incubated for 10 -60 min with TRLs + ApoCIII and protein phosphorylation was determined using phospho-specific antibodies against Akt (Ser473). As shown in Figure 6E , even though both TRLs could activate this pathway, TRLs + ApoCIII had a stronger effect on the Akt pathway. Wortmannin, which is an Akt inhibitor, could abolish this difference ( Figure 6F ). These data suggested that the Akt pathway may be involved in ApoCIIImediated SMC proliferation.
ROS may mediate the activation of SMCs by TRLs 1 ApoCIII
Oxidative stress has been widely identified as a substantial promoting factor for vascular SMC proliferation. In order to evaluate the effect of ApoCIII on ROS production, we measured superoxide production in the aorta ( Figure 2D) , and 8-isoprostane, a lipid peroxidation byproduct, in the plasma of Ldlr2/2 control, ApoCIIItg/Ldlr2/2, and ApoCIII/Ldlr DKO mice after 3 months on an atherogenic diet ( Figure 7A ). ApoCIIItg/Ldlr mice had a significantly higher plasma level of 8-isoprotane compared with ApoCIII/Ldlr DKO or Ldlr2/2 mice, and there was no statistically significant difference shown between ApoCIII/Ldlr DKO and Ldlr2/2 mice. As regards neointimal formation, immunohistochemical staining of 4-hydroxynonenal (4HNE, a marker of lipid peroxidation) revealed that 4HNE production was increased in lesion sites of ApoCIIItg mice compared with WT and ApoCIII2/2 mice ( Figure 7B) .
Next, we incubated SMCs with TRLs + ApoCIII for 48 h in vitro and measured intracellular ROS production using the DCFH-DA assay. Even though both TRLs promoted ROS production, there was a statistically significant difference between the effect of TRLs + ApoCIII and TRLs2ApoCIII ( Figure 7C) .
To investigate further the role of ROS in the proliferating effect of TRLs + ApoCIII, we incubated SMCs with TRLs in the presence of N-2-mercaptopropionylglycine (MPG; 1000 mM), a ROS scavenger. Significantly, scavenging ROS abolished the proliferating effect of TRLs + ApoCIII. MPG also eliminated the difference in Akt phosphorylation caused by TRLs + ApoCIII and TRLs2ApoCIII ( Figure 7D ).
Discussion
For the first time, we have shown that HTG, caused by the ApoCIII transgene, promotes restenosis through the use of various transgenic and knockout animal models. Moreover, we demonstrated for the first time that ApoCIII (in combination with TRLs) had an additional effect on SMC proliferation, using authentic TRLs + ApoCIII isolated from ApoCIIItg/GPIHBP12/2 and ApoCIII/GPIHBP1 DKO mice.
Studies that analysed the relationship between ApoCIII transgene and atherosclerosis have produced different results. It was previously shown that with the Ldlr2/2 background, human ApoCIII transgenic mice [called the familial combined hyperlipidaemia (FCHL) model] produced increased atherosclerotic lesions compared with WT mice. 38 However, Ebara et al. failed to find any difference between ApoCIII transgenic and WT mice with an ApoE2/2 background. 39 Therefore, Apolipoprotein CIII and atherogenosis we established our ApoCIIItg/Ldlr2/2 and ApoCIII/Ldlr DKO models. Our results were consistent with the FCHL model, even though plasma TG levels decreased after a Western diet in the FCHL model while it increased significantly in our animal models. We attribute the conflicting conclusions of Ebara et al. to: (i) the use of female mice in their study, and the gender differences in lipid levels and susceptibility to atherosclerosis documented in early investigations; 40 -42 and (ii) the base levels of atherosclerotic lesions in ApoE2/2 mice were too high, which could obscure the effect of HTG caused by the ApoCIII transgene because HTG was shown to exert only a minor effect on atherogenesis in murine models, compared with hypercholesterolaemic mice.
1,2
Our findings also showed that ApoCIIItg mice exhibited more significant neointimal formation than ApoCIII2/2 or WT mice. However, under the conditions used, we did not see a statistical difference in atherosclerotic lesions between ApoCIII/Ldlr DKO and Ldlr2/2 mice, or any difference in neointimal formation between ApoCIII2/2 and WT mice. This seems in contradiction to some human studies, in which a loss-of-function mutation (e.g. R19X) in the gene encoding ApoCIII tends to have a cardioprotective effect and is associated with a reduced risk of coronary heart disease. 13,43 -46 As we saw no difference in ApoCIII2/2 mice, we do not think it is merely a sample size problem. The sample size used in this study was large and the results are reproducible (with or without the Ldlr2/2 background). Since loss of function of ApoCIII has a protective effect in human CVD, we attribute this to the species differences between mice and humans. We expected to see the protective effect in ApoCIII2/2 mice, but, unfortunately, we did not find evidence for this using the present mouse models. This is an issue which is unresolved in the present study, but we recorded our findings faithfully. The discrepancy of the role of ApoCIII in atherogenesis in transgenic and knockout mouse models may be related to the difference in ApoCIII between humans and mice. We used human transgenic mice which overexpressed human ApoCIII, but knockout mice which lack endogenous mouse ApoCIII. It had been shown in human population studies that the group of patients with higher ApoCIII levels had a higher incidence and severity of atherosclerosis than those with lower ApoCIII levels. 20, 47 Our in vitro and in vivo results in the present study have demonstrated that human ApoCIII indeed could be a causative factor of atherogenesis and restenosis. In contrast, the deletion of mouse ApoCIII is not exactly equivalent to ApoCIII loss-of-function mutations in humans because the differences in structural and functional characteristics of ApoCIII between mouse and human may have an impact on atherogenesis and restenosis to a different but significant extent. Overall, this problem is often encountered when studying pathogenic factors or risk factors with a minor effect. In a complex disease, such as atherosclerosis, many risk factors contribute only ,5% to the whole pathological process. Therefore, although exciting new discoveries have been made by large-scale population-based epidemiological studies, as is the case of ApoCIII null mutations for protection from coronary artery disease, 14,15 more careful experimental designs will be needed to reflect these findings and to explore further the underlying mechanisms. Perhaps an ideal study to address this issue would be the creation of three animal models that all do not express mouse endogenous ApoCIII, one expressing human ApoCIII at similar levels to humans, one expressing human ApoCIII at higher levels in comparison with the other one without endogenous murine ApoCIII as controls. Under such conditions, consistent results regarding the role of human ApoCIII on mouse atherogenesis and restenosis could be addressed more appropriately. Of course, this type of study is not needed for genetic factors with a major impact on certain phenotypes such as LDL receptor and ABC-A1 on cholesterol metabolism and atherosclerosis. Except for ECs and macrophages, little is known about the effect of TRLs on SMCs. We therefore cultured rat aortic SMCs and incubated them with authentic TRLs to investigate the impact of TRLs on SMC proliferation in vitro and to what extent ApoCIII in TRLs participates in this progress. There were two technical procedures that made our in vitro finding unique and reliable. First, the authentic TRLs + ApoCIII were isolated from ApoCIIItg/GPIHBP12/2 and ApoCIII/GPIHBP1 DKO mice. This guaranteed TRL activity under physiological conditions. Secondly, we added TRLs normalized to TG content, instead of protein. This is because: (i) TRLs, unlike LDL and other denser lipoproteins, consist mainly of TG, not proteins; and (ii) we intended to investigate the role of ApoCIII in TRLs and whether the plasma ApoCIII concentration positively correlates with TG concentration.
In the present study, we showed that TRLs + ApoCIII may promote SMC proliferation via the Akt signalling pathway. This is consistent with a previous study showing that VLDLs may bind to VLDL receptors of SMCs and induce cell proliferation by causing Akt phosphorylation. 33 We also showed that ROS may mediate the proliferation of SMCs caused by TRLs + ApoCIII since scavenging ROS could significantly abolish the proliferation effect and Akt phosphorylation between TRLs + ApoCIII and TRLs2ApoCIII.
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